METTL3 and acute myeloid leukemia: Taken together, in this study, eltrombopag was identified as a METTL3-14 allosteric inhibitor with anti-leukemic activity against AML, which could provide a potential opportunity for the development of new drug candidates for AML via further optimization of the structure of eltrombopag at the binding site.